Advertisement
 
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Radix BioSolutions Adopts Gyrolab xP Workstation

May 3, 2010 6:54 am | News | Comments

Radix BioSolutions will integrate a Gyrolab xP workstation into its immunoassay development programs.

TOPICS:

Single-channel Microplate Reader

May 3, 2010 6:51 am | Product Releases | Comments

The Biochrom Asys UVM340 monochromator-based plate reader lets users select the exact wavelength to measure optical density for an application.

TOPICS:

Children With Autism Frequently Receive Psychotropic Medications

May 3, 2010 6:49 am | News | Comments

Behavioral interventions typically are the first line of treatment to manage unwanted behaviors in children with autism spectrum disorders (ASDs). If behaviors do not improve, medications frequently are added to the mix.

TOPICS:
Advertisement

HAMA Blocker

May 3, 2010 6:45 am | Product Releases | Comments

amsbio has introduced TRU Block, a highly potent reagent that actively blocks the heterophilic antibody (HA) interference in immunoassays including Human Anti-Mouse Antibody (HAMA) interference.

TOPICS:

Gene Mutations Linked to Autism

May 3, 2010 6:44 am | News | Comments

Although there is no known cause of autism, studies have shown that mutations in several genes are associated with the developmental brain disorder. New research has uncovered two additional genes that may be involved with autism.

TOPICS:

Automated Cell-Based ELISA Procedures

May 3, 2010 6:42 am | Product Releases | Comments

Agilent Automation Solutions has configured its BioCel System that to allow laboratories to fully automate cell-based ELISA procedures thereby reducing the risk of human error, contamination, and time spent on tedious manual procedures.

TOPICS:

Junk DNA Drives Cancer Growth

May 3, 2010 6:39 am | News | Comments

Researchers from the University of Leeds, UK, the Charité University Medical School and the Max Delbrück Centre for Molecular Medicine (MDC) in Berlin, Germany, have discovered a new driving force behind cancer growth.

TOPICS:

FDA Approves sNDA for CREON

May 3, 2010 6:34 am | News | Comments

Abbott announced that the U.S. Food and Drug Administration approved the supplemental New Drug Application for CREON delayed-release capsules.

TOPICS:
Advertisement

Successful Phase 3 Trial for Belatacept

May 3, 2010 6:26 am | News | Comments

Two-year results from phase 3 clinical trials show the experimental immunosuppressive drug belatacept can better preserve kidney function in kidney transplant recipients while preventing graft rejection when compared with the standard immunosuppressive drug cyclosporine.

TOPICS:

Study Implicates Rewired Interactions In Cancer

May 3, 2010 6:07 am | News | Comments

Genes interact in complex networks that govern cellular processes, much like people connect a social network through relationships.

TOPICS:

New Tool Enables Wider Analysis Of Deep Sequencing

May 3, 2010 6:04 am | News | Comments

Scientists seeking to understand the machinations of the proteins behind genetics have a powerful new tool at their disposal, courtesy of researchers at the Stanford University School of Medicine.

TOPICS:

Pitt Researchers Explain Omega-3 Abilities

May 3, 2010 5:57 am | News | Comments

Scientists at the University of Pittsburgh School of Medicine have located a group of new mediators that not only can explain how omega-3 fatty acids reduce inflammation, but also hint at novel treatments for a host of diseases linked to inflammatory processes.

TOPICS:

McNeil Issues Children's Medicine Recall

May 3, 2010 5:49 am | News | Comments

The Food and Drug Administration is investigating a health-care company for possible other problems following its recall of more than 40 over-the-counter infant's and children's liquid medications.

TOPICS:

FDA Approves Breakthrough Cancer Therapy Provenge

April 30, 2010 10:30 am | by Matthew Perrone, AP Business Writer | News | Comments

Dendreon Corp.'s Provenge, a first-of-a-kind prostate cancer treatment that uses the body's immune system to fight the disease received federal approval, offering an important alternative to more taxing treatments like chemotherapy.

TOPICS:

Simulation Software

April 30, 2010 7:08 am | Product Releases | Comments

The time-consuming scientific research behind drug discovery can now be accelerated with the launch of AMBER 11, a software tool that enables bio-scientists to harness the power of supercomputing on their desktop PC.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading